An isogenic cell line was created to model cancer ... ALK. We employed the CRISPR/Cas9 genome editing platform for the generation of the desired targeted genomic rearrangement in the A549 lung ...

Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication. Alecensa ...

Alectinib is recommended, within its marketing authorisation, as an option for the adjuvant treatment of stage 1B (tumours 4 cm or larger) to 3A ALK-positive non-small-cell lung cancer (NSCLC) after ...

Alectinib (Alecensa) is available on the NHS. It is a possible adjuvant treatment for stage 1B (tumours 4 cm or larger) to 3A ALK-positive non-small-cell lung cancer (NSCLC) after surgery in adults.

ALK lung cancer is caused by a gene mutation in cancer cells. Lung cancers with a mutation tend to be found in non-smokers or light smokers, and often affect people who are younger and fitter than ...

This research has gained worldwide attention as an indicator of new possibilities; not only for lung cancer, but across the entire spectrum of cancer treatments. In order to discover cancer genes, ...

The FDA has approved Roche’s Alecensa for the treatment of early stage resected non-small cell lung cancer, or NSCLC ... makes Alecensa the first and only ALK inhibitor therapy approved for ...

Research collaborators at the Rogel Cancer Center’s Judith Tam ALK Lung Cancer Research Initiative presented positive preclinical data reporting that Reqorsa induced apoptosis in alectinib ...